BioSig’s Division NeuroClear Technologies Signs a Research Agreement with the University of Minnesota

    NEXT STORY
    Y-mAbs Signs License Agreement with SciClone for DANYELZA® (naxitamab-gqgk) and Omburtamab in China
    PREV STORY
    Bavarian Nordic Announces Top-line Results from Phase 2 Clinical Trial of BN-Brachyury in Chordoma
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Cempra Reports Third Quarter 2016 Financial Results and Provides Corporate Update

    CHAPEL HILL, N.C., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage ...

    author_avatar
    NASDAQ Market News

    Celsion Announces FDA Clearance of the OVATION II Study for the Evaluation of GEN-1 Immunotherapy to Treat Newly Diagnosed Stage III/IV Ovarian Cancer

    GEN-1 to Enter the Clinic in Mid-2018 Following a Phase IB Trial Which Demonstrated ...

    author_avatar
    NASDAQ Market News

    Decision by the Board of Directors to acquire own shares

    author_avatar
    NASDAQ Market News